Alembic Pharmaceuticals has made the audio recording of its post-results conference call available to investors via its official website. The call took place on August 4, 2026, providing stakeholders with an opportunity to discuss the company’s recent financial performance and strategic outlook. This disclosure follows the company’s earlier intimation to stock exchanges dated July 27, 2026, ensuring transparency and timely access to material information for shareholders and analysts.

The audio file is hosted at the company’s quarterly results section, allowing for easy retrieval by market participants. Manisha Saraf, Company Secretary at Alembic Pharmaceuticals Limited, submitted the hosting details to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd. (NSE) on August 4, 2026. The submission serves as a formal record that the mandatory post-result discussion has been conducted and archived as per regulatory requirements.

Disclosure Details

The company communicated the availability of the recording through a formal letter addressed to the Department of Corporate Services at BSE Limited and the Listing Department at NSE. The submission references the initial results announcement made on July 27, 2026, linking the conference call directly to the reported financial outcomes. By hosting the audio online, Alembic Pharmaceuticals ensures that all investors, regardless of their ability to attend the live event, can access the same information.

Regulatory Compliance

This action aligns with listing regulations requiring listed entities to conduct conference calls after announcing financial results and to make recordings available for public access. The prompt submission on the same day as the call demonstrates adherence to compliance timelines. The recording remains accessible at https://alembicpharmaceuticals.com/quarterly-results , serving as a permanent record of the management’s commentary on the quarter’s performance. No additional financial metrics or operational updates were disclosed in this specific filing, which focuses solely on the archival of the conference call audio.

Alembic Pharmaceuticals has announced plans to introduce more than 15 new products in the United States by FY27. The development underscores the company's continued focus on strengthening its footprint in the U.S. pharmaceutical market, which remains a key geography for Indian generic drug manufacturers.

U.S. Market Expansion Plans

The company's pipeline targets the introduction of over 15 new products in the U.S. by FY27. The following table summarizes the key details of the announced expansion plan:

Alembic Pharmaceuticals' plan to launch more than 15 new products in the U.S. by FY27 highlights the company's commitment to growing its international generics business. The U.S. remains a critical market for Indian pharmaceutical companies, given its scale and demand for affordable generic medicines.